REVIEW Bevantolol acts as both a beta blocker and a calcium channel blocker for the treatment of angina pectoris and hypertension. It possesses a relatively high degree of antagonistic selectivity for beta 1-adrenoceptors, thereby inhibiting normal epinephrine-mediated sympathetic actions such as increased heart rate. This has the effect of decreasing preload and blood pressure. It is devoid of intrinsic sympathomimetic activity and possesses only weak local anaesthetic properties. Interestingly, bevantolol has been shown to cause a lowering effect on peripheral vascular resistance.
Holmes, Ann; Meyer, Robert Frederick beta-Adrenergic blocking 1-(3,4-dimethoxyphenethylamino)-3-phenoxy-2-propanols Ger. Offen. (1973), DE 2259489 A1 19730705.
Hoefle, Milton L.; Hastings, Stephen G.; Meyer, Robert F.; Corey, Ruth M.; Holmes, Ann; Stratton, Charlotte D. Cardioselective beta-adrenergic blocking agents. 1. 1-[(3,4-Dimethoxyphenethyl)amino]-3-aryloxy-2-propanols Journal of Medicinal Chemistry (1975), 18(2), 148-52.
Hoekstra, Marvin S. 1-(3,4-Dimethoxyphenethylamino)-3-(substituted phenoxy)-2-propanols Eur. Pat. Appl. (1985), EP 165682 A1 19851227.
Vaughan Williams EM: Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions. J Clin Pharmacol. 1987 Jul;27(7):450-60.
For research use only. Not for diagnostic or therapeutic use. Not for human use. AK Scientific, Inc. does not sell to individuals. If you are a first-time customer, please email for review at least two official business documents issued by your local jurisdiction, state/province, or country.